Uniphos Enter. (UNIENTER)
TurnaroundFairStock Score: 4/100 — RISKY
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹95.36 |
| Market Cap | ₹1,326.38 Cr |
| P/E Ratio | 32 |
| ROCE | 0.06% |
| ROE | 0.77% |
| Dividend Yield | 3.67% |
| Profit Growth | -61.62% |
| Debt/Equity | — |
| Sales Growth | -97.31% |
| Promoter Holding | 73.79% |
| 52-Week Range | ₹78.55 — ₹158 |
| Sector | Chemicals & Petrochemicals |
| Book Value | ₹351.82 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
We have a curious situation at Uniphos Enterprises. The stock trades at ₹108.19, against a book value of ₹371.71 per share — a 71% discount. That is the kind of price that catches my eye, but as Ben Graham taught us, a bargain is only a bargain if the asset can be turned into earnings or cash flow. Here, the company earned just ₹0.77 on every ₹100 of equity in the last year. ROE is 0.77%, ROCE is 0.06%. This is not a business; it is a box of assets earning almost nothing. Sales have collapsed by 100%, and the latest quarter showed zero revenue and a ₹1 crore loss. The P/E of 37.61 is meaningless when the 'E' is so small and likely non-operating. Profit growth of 45.7% means little from such a low base. On the positive side, the company appears to have no significant debt, and promoters own 73.79%, giving them a strong reason to think like owners. The Piotroski score of 6 suggests the balance sheet isn't deteriorating rapidly. But with returns this poor, the margin of safety is in the assets, not the earnings. Can the market trust the book value? At a market cap of ₹746 crore versus a book value of roughly ₹2,564 crore, the discount is enormous. Either the assets are misvalued, or the market knows something that doesn't reflect realisable worth. I would not rush in. I need to see a catalyst for value release — dividends, buybacks, asset sales, or a revival of earning power. Without that, a 0.29 price-to-book can remain a permanent discount. This is an asset play, not a compounder. I'd keep it on my watchlist, but only buy if the company starts proving that a rupee of book value can become a rupee in my pocket.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer